LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Home・Aktien・Dynavax Technologies Corp

Dynavax Technologies Corp

Geschlossen

Branche Gesundheitswesen

11.18 2.19

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

11.17

Max

11.28

Schlüsselkennzahlen
By Trading Economics
Einkommen	20M 11M
Verkäufe	23M 74M
KGV Branchendurchschnitt	160.43 103.001
EPS	0.08
Gewinnspanne	15.428
Angestellte	408
EBITDA	26M 18M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+119.34 upside

Dividenden
By Dow Jones
Nächstes Ergebnis	31. Okt. 2024

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-26M 1.5B
Vorheriger Eröffnungskurs	8.99
Vorheriger Schlusskurs	11.18

Nachrichtenstimmung

By Acuity

50%

97 / 365 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Neutral Evidence

10.88 / 11.32 Unterstützung & Widerstand

Dynavax Technologies Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Sept. 2024, 01:45 UTC

Ergebnisse

Preview -- Barron's

13. Sept. 2024, 20:03 UTC

Top News

Walgreens to Pay $106.8 Million Over Alleged Fraudulent Healthcare Billings

15. Sept. 2024, 23:47 UTC

Market Talk

Gold Edges Higher Amid Mild Dollar Weakness -- Market Talk

15. Sept. 2024, 23:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Sept. 2024, 23:03 UTC

Market Talk

Australian Bond Traders Watchful as Fed Easing Nears -- Market Talk

15. Sept. 2024, 16:52 UTC

Top News

Boeing Machinist Strike Adds Cash Crunch to New CEO's Rescue Mission -- WSJ

15. Sept. 2024, 09:30 UTC

Top News

Interest Rates Are Too High. The Fed Should Cut by a Half Point. -- WSJ

15. Sept. 2024, 07:00 UTC

Top News

World's Biggest Hedge Fund Sells Apple, Eli Lilly Stock, and Buys Microsoft, Moderna -- Barrons.com

14. Sept. 2024, 14:09 UTC

Top News

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- Update 1 -- WSJ

14. Sept. 2024, 13:25 UTC

Top News

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- WSJ

14. Sept. 2024, 09:30 UTC

Top News

Why a Fed Rate Cut Won't Solve the Housing Wealth Gap -- WSJ

14. Sept. 2024, 09:30 UTC

Top News

Americans Are Falling Behind on Their Bills. Wall Street Is Alarmed. -- WSJ

14. Sept. 2024, 03:00 UTC

Top News

What Scared Ford's CEO in China -- WSJ

14. Sept. 2024, 03:00 UTC

Top News

What Scared Ford's CEO in China -- WSJ -2-

14. Sept. 2024, 00:01 UTC

Top News

Why 96% of Boeing's Machinists Voted to Go on Strike -- Update

13. Sept. 2024, 21:14 UTC

Top News

Why 96% of Boeing's Machinists Voted to Go on Strike -- WSJ

13. Sept. 2024, 21:06 UTC

Top News

Starliner Astronauts Say NASA Ran Short of Time to Test Boeing Craft -- WSJ

13. Sept. 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

13. Sept. 2024, 20:47 UTC

Market Talk

Saudi Arabia Credit Outlook Raised to Positive on Economic Investments -- Market Talk

13. Sept. 2024, 20:44 UTC

Akquisitionen, Fusionen, Übernahmen

Schlumberger Stock Was Once as Hot as Nvidia. Why It's a Buy. -- Barrons.com

13. Sept. 2024, 20:41 UTC

Top News

Berkshire Hathaway's Stock Is So Rich Even Berkshire Is Buying Less of It -- Update

13. Sept. 2024, 20:31 UTC

Ergebnisse

These Stocks Moved the Most Today: Adobe, Boeing, Trump Media, Oracle, Uber, RH, Moderna, Etsy, and More -- Barrons.com

13. Sept. 2024, 20:13 UTC

Akquisitionen, Fusionen, Übernahmen

BlackRock: Expects to Close Previously Announced Acquisition of Global Infrastructure Partners on Oct 1 >BLK

13. Sept. 2024, 20:10 UTC

Akquisitionen, Fusionen, Übernahmen

BlackRock Announces Expected Closing Date For Acquisition Of Global Infrastructure Partners >BLK

13. Sept. 2024, 20:02 UTC

Akquisitionen, Fusionen, Übernahmen

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13. Sept. 2024, 20:02 UTC

Akquisitionen, Fusionen, Übernahmen

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13. Sept. 2024, 19:44 UTC

Market Talk

Treasury Yields Fall as Odds of 50bp Fed Cut Rise -- Market Talk

13. Sept. 2024, 19:20 UTC

Market Talk

Crude-Oil Futures End Week With Small Gains -- Market Talk

13. Sept. 2024, 19:09 UTC

Market Talk

U.S. Natural-Gas Futures Post Weekly Gain -- Market Talk

13. Sept. 2024, 18:01 UTC

Market Talk

Gold Analysts Call For New Leg Of Rally -- Market Talk

Peer-Vergleich

Kursveränderung

Dynavax Technologies Corp Prognose

Kursziel

By TipRanks

119.34% Vorteil

12-Monats-Prognose

Durchschnitt 24.5 USD 119.34%

Hoch 29 USD

Tief 15 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Dynavax Technologies Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Dynavax Technologies Corp – Dist abgegeben haben.

Technischer Score

By Trading Central

10.88 / 11.32Unterstützung & Widerstand

The bullish and bearish events are balanced.

Recent bearish events outweigh bullish events.

There are no events.

Stimmung

By Acuity

97 / 365 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Dynavax Technologies Corp

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing novel vaccines. The Company's products include HEPLISAV-B and CpG 1018TM. The HEPLISAV-B is for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The Company also manufactures and sells CpG 1018TM, the adjuvant used in HEPLISAV-B. The Company also engaged in developing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships.